Newport Beach, California — September 4, 2025 — Leads & Copy — Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc., has announced the completion of Phase II of its AI Development Program with Yuva Biosciences, Inc. As part of the objective, YuvaBio delivered to Northstrive a shortlist of small molecule candidates believed to have the potential to promote mitochondrial health to combat obesity and cardiac diseases.
YuvaBio completed Phase II by compiling a targeted collection of compounds drawn from 12 curated libraries, designed to include molecules with activity across key disease areas—obesity, cardiometabolic disorders, and lipid & glucose metabolism—thereby aligning closely with Northstrive Bio’s therapeutic focus. MitoNova™, YuvaBio’s AI platform, screened the aggregated chemical space to evaluate predicted impact on a specified target involved in muscle preservation and metabolic health. YuvaBio presented Northstrive with a shortlist of compounds ready for biological validation in vitro. Northstrive has the opportunity to review the list of compounds and analyze their potential to be advanced to experimental testing and clinical development.
Northstrive Biosciences Inc. focuses on the development and acquisition of cutting-edge aesthetic medicines. Northstrive Biosciences’ lead asset, EL-22, leverages an engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.
PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries.
IR Contact:
IR@pmgcholdings.com
Source: Northstrive Biosciences Inc.
